Genmab CEO says Janssen should "show respect" as royalty strife nears conclusion

Danish biotech company Genmab and Johnson & Johnson’s pharmaceutical arm Janssen have been fighting it out over royalty payments for a year. As the verdict draws near, Genmab CEO Jan van de Winkel has taken a jab at Janssen, saying it ought to show Genmab some respect.

Jan van de Winkel, CEO of Genmab | Photo: PR / Genmab

For around a year, Genmab and its US-based partner Janssen, the pharmaceutical arm of Johnson & Johnson, have been in a legal battle concerning royalty payments from the latter to the Danish biotech company, Danish business daily Børsen reports.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs